Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies

The goal of this educational program is to enhance the efficacy and safety of stem cell mobilization for donors of patients with multiple myeloma (MM) by spreading information of the most current and effective methods to physicians. Collecting stem cells for transplantation is necessary for many patients, as transplantation persists as an effective strategy for myeloma. New collection methods are arising and improving stem cell mobilization, and physicians should be kept up to date on the new options and guidelines for protecting donor safety.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing Co., Ltd. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals. 

This enduring material is approved for 1 year from the date of original release, June 5, 2017 to June 4, 2018.

Target Audience

This activity has been developed and isintended for transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives


• Identify existing and emerging strategies for optimizing stem cell mobilization

• Select optimal CD34 goals and strategies to achieve the best results

• Identify barriers to autologoustransplants in MM

Additional information

Contact

Name: 
Garland Branch
Phone Number: 
+1 (434) 817-2000
Email: 
gtbranch@cjp.com
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
06/05/2017
Course expires: 
06/04/2018
Cost:
$0.00

FACULTY & DISCLSOSURE

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships.  The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant: 

Parameswaran N. Hari, MD, MRCP, MS, discloses that he has received honoraria and served as a consultant for Sanofi, Celgene, and Takeda.

Luciano Costa, MD discloses that he has received honoraria and research funding from Sanofi and from Amgen, and has received honoraria from Celgene. He has served also as a consultant for Sanofi.

John R. Wingard, MD, has no relevant financial relationships to disclose.

The educational content of this program has been peer reviewed by The Medical College of Wisconsin. The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose. Signed disclosures are on file at The Medical College of Wisconsin.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.